<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20150905023897N7</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-12-11</date_registration>
      <primary_sponsor>Tarbiat modares University</primary_sponsor>
      <public_title>The effect of apple cider vinegar tablet on metabolic syndrome and insulin resistance in PCOS patients: A randomized double-blind trial</public_title>
      <acronym></acronym>
      <scientific_title>The effect of apple cider vinegar tablet on metabolic syndrome and insulin resistance in PCOS patients: A randomized double-blind trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>94</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/72397</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we will use the restricted randomization method (block randomization type). Blocking is often with the purpose Creating a balance in the number of samples assigned to each of the studied groups should be used. This feature allows researchers to have the same number of samples assigned to each of the studied groups in cases where intermediate analyzes are needed during the sampling process.
The size of all the blocks is equal and we will have 4 blocks in this two-group experiment (including 2 participants in the intervention group and 2 participants in the control group).
The randomization tool is also used from random sequence generation software (random allocation software), which in addition to simple randomization, these random sequence generation software are also capable of generating random sequence by block method.
In order to conceal, we will use Concealment Allocation, which refers to the method used to perform a random sequence on the participants in the study, so that the allocated group is not known before the allocation of the individual. By using sealed and non-transparent envelopes with a random sequence (envelopes opaque, sealed, numbered Sequentially (in this method, each of the random sequences created on a registration card, and the cards inside the letter envelopes) They are placed in order.
 In order to maintain a random sequence, the outer surface of the envelopes is numbered in the same order. Then the lid of the letter envelopes is glued and placed in a box in order. At the time of the registration of the participants, based on the order of entry of the qualified participants into the study, one of the envelopes will be opened in order and the assigned group of that participant will be determined, Blinding description: The researcher and patient will be unaware of the treatment and grouping of the study. For this purpose, apple cider vinegar tablet and placebo are coded by a research center. The lead researcher treats patients in a double-blind manner based on the drug package code. The code for the drug package is recorded on the personal information form, and the researcher who completes the information form will not be informed of the type of treatment.</study_design>
      <phase>2</phase>
      <hc_freetext>Condition 1: Metabolic syndrome in PCOS patients. Condition 2: Insulin resistance in PCOS patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Treatment by Apple cider vinegar tablet  500 mg. Intervention 2: Control group: Treatment by placebo of Apple cider vinegar tablet.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Information on the main outcome of the study

When:
1403

To whom:
Academic researchers

Conditions:
Use for further research in the future

Where to obtain:
Email Addressing Responsible for Study

How to obtain:
Submit a request to study and follow up

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shahideh Jahanian Sadatmahalleh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jalal E Al Ahmad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۱۱۷۱۳۱۱۶</zip>
        <telephone>+98 21 2230 6480</telephone>
        <email>Shahideh.jahanian@modares.ac.ir</email>
        <affiliation>Tarbiat modares University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shahideh Jahanian Sadatmahalleh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Jalal E Al Ahmad</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۱۱۷۱۳۱۱۶</zip>
        <telephone>+98 21 2230 6480</telephone>
        <email>shahideh.jahanian@modares.ac.ir</email>
        <affiliation>Tarbiat Modares University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>fertility age between 15-49 years
Iranian women
No pregnancy
Have at least literacy for read and write
No Mellitus Diabets according to primary FBS
No chronic diseases affecting PCOS (such as congenital adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, thyroid dysfunction)
Lack of consumption Anti lipids and Anti hypertensive and anti coagulative drugs during the last three months
People are willing to participate in the study</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>49 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>People with drug side effects
Individuals unwilling to continue to participate in the study
failure to comply with treatment protocol</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Treatment by Apple cider vinegar tablet  500 mg</i_keyword>
      <i_keyword>Control group: Treatment by placebo of Apple cider vinegar tablet</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Blood level of FBS. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.</prim_outcome>
      <prim_outcome>Blood level of Insulin. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.</prim_outcome>
      <prim_outcome>Level of Triglyceride. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.</prim_outcome>
      <prim_outcome>Level of  total cholesterol. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.</prim_outcome>
      <prim_outcome>Blood  level of LDL. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.</prim_outcome>
      <prim_outcome>Blood  level of HDL. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.</prim_outcome>
      <prim_outcome>Blood level of testostrone. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test.</prim_outcome>
      <prim_outcome>Weight. Timepoint: First of study and 12 weeks after intervention. Method of measurement: use of scale.</prim_outcome>
      <prim_outcome>Waist to hip ratio. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of meter.</prim_outcome>
      <prim_outcome>Level of systolic and diastolic blood pressure. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of mercury barometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Menstrual dysfunction such as: Oligomenorrhea and amenorrhea. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Patient statements.</sec_outcome>
      <sec_outcome>Clinical hyperandrogenemia. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Blood biochemistry test and clinical symptom.</sec_outcome>
      <sec_outcome>Ultrasound view of the ovaries. Timepoint: First of study and 12 weeks after intervention. Method of measurement: Use of ultrasound.</sec_outcome>
      <sec_outcome>Sexual function. Timepoint: First of study and 12 weeks after intervention. Method of measurement: FSFI questionnaire.</sec_outcome>
      <sec_outcome>Quality Of life. Timepoint: First of study and 12 weeks after intervention. Method of measurement: MPCOSQ questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tarbiat modares University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-30</approval_date>
        <contact_name>Ethics committee of Tarbiat Modares university</contact_name>
        <contact_address>Jalal E Al Ahmad Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
